Drilldown: Medicines

None (2) · Apixaban (1) · Dexmethylphenidate (1) · Sildenafil (1)

Ajovy (1) · Eliquis (1) · Emgality (1) · Focalin, Focalin XR (1) · Viagra, Revatio (1)

Anti-CGRP ligand monoclonal antibody (2) · CNS stimulant (1) · NDRI (1) · PDE5 Inhibitor (1) · Psychostimulant (1) · [[:Category:Anticoagulants|Anticoagulant]] (1) · [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] (1) · [[:Category:DOACs|Direct oral anticoagulant (DOAC)]] (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) · '"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1)

None (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1)

None (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 2.5 mg, 5 mg tablets (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1)

None (1) · 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 675 mg/quarter (1)

IV (Revatio) (1) · Oral (3) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

12 hours (1) · IR 4–6 h; XR 8–12 h (1) · Monthly dosing (1) · Monthly or quarterly dosing (1) · ~4 h (1)

2.2 h (IR parent); ~3 h (XR parent) (1) · ~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1) · ~27 days (1) · ~31 days (1) · ~4 h (1)

Not formally established (1) · Not formally established (high SC) (1) · ~22–25% (1) · ~40% (1) · ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1)

None (1) · Category B (1) · Category C (1) · Limited data; avoid (2)

Rx (2) · Rx-only in US (1) · Schedule II (1) · [[USLegal:Prescription only|Rx-only]] in US (1)